Humanin Research Review: A Mitochondrial-Derived Peptide and Its Open Questions

Humanin is a short peptide with an unusual biography: it was discovered in a functional screen for neuronal survival factors, and its coding sequence was then found to match an open reading frame in the mitochondrial genome. Two decades on, the questions of what it binds and how it acts are still open. This review of humanin research follows the primary papers, sets the two leading mechanisms side by side, and marks where the evidence stops. It is a literature review of a catalogue compound, not a guide to using it.
What humanin is
Humanin is a 24-amino-acid peptide, sequence MAPRGFSCLLLLTSEIDLPVKRRA. It was first reported by Hashimoto et al., 2001, who used functional expression screening to identify a cDNA whose product abolished neuronal cell death caused by several familial Alzheimer's disease genes and by amyloid-beta. The PubMed record of that paper carries a published erratum, which is worth noting for anyone citing it.
Two years later, Guo et al., 2003 reported that the mitochondrial genome contains an identical open reading frame. That is the basis for classing humanin as a mitochondrial-derived peptide, a group that also includes MOTS-c, reviewed by Kim et al., 2021.
Humanin research: the primary papers
2001: the neuronal rescue screen
The founding study was a cell-based screen. Its readout was survival of neuronal cells exposed to insults linked to familial Alzheimer's disease. That is a specific, well-defined model, and it is the origin of the large body of later work in Alzheimer's cell and mouse models. It is not, and did not claim to be, evidence about disease in people.
2003: an intracellular partner, Bax
The Nature paper by Guo and colleagues reported that humanin binds the pro-apoptotic protein Bax and prevents its translocation from the cytosol to mitochondria, a step in the intrinsic apoptosis pathway. That gives a direct, intracellular account of how a peptide could reduce cell death.
2010: a cell-surface receptor complex
A review by Matsuoka and Hashimoto, 2010 summarised a different route: humanin acting from outside the cell through a receptor complex related to the interleukin-6 receptor family, involving CNTFR-alpha, WSX-1 and gp130. The same review describes activity in various murine Alzheimer's disease models.
2021: the mitochondrial-derived peptide frame
The Kim review places humanin alongside MOTS-c and discusses research on cellular senescence, chronic inflammation and cognitive decline in the context of age-related disease. It is a review of preclinical work and of circulating peptide levels, and its framing is a research agenda rather than a set of findings about people. Our separate review of SS-31, MOTS-c and NAD+ covers the other mitochondrial-derived peptide in more detail.
Two mechanisms, not reconciled
The Bax model and the receptor model are not mutually exclusive, but they describe different biology. One requires the peptide inside the cell, interacting with apoptotic machinery. The other requires it outside, signalling through a cytokine-receptor-like complex. Other binding partners have also been proposed in the literature. None of these accounts has displaced the others, and the cited sources do not claim that any one of them explains all the reported observations. For a reader, the practical consequence is simple: a description of humanin's "mechanism" in any single sentence is a simplification of an unsettled question.
Where the evidence stops
- Preclinical only. The mechanistic and functional work is in cells and rodents.
- No interventional human trials. Registered human studies measure humanin levels, for example in blood, as a biomarker. None found gives the peptide to people.
- Biomarker studies are observational. An association between circulating humanin and a condition is not evidence that the peptide affects that condition.
- Not an approved product. No approved humanin product was found in Drugs@FDA.
The summary: an interesting origin story, two credible but unreconciled mechanisms from cell work, an active rodent literature in Alzheimer's models, and a human literature limited to measurement.
Characterising a 24-residue peptide
Humanin has three features that shape how a lot is analysed. First, it contains a single cysteine; free thiols can oxidise to form disulfide-linked dimers, which appear as a distinct species at roughly double the mass. Second, the N-terminal methionine can oxidise to methionine sulfoxide, a +16 Da shift that mass spectrometry detects readily. Third, the central run of four leucines makes the peptide notably hydrophobic, which affects its retention on reverse-phase HPLC and its tendency to aggregate.
Several analogues with single residue substitutions appear in the literature, so the certificate's mass result should be read against the native sequence above. Each lot's certificate of analysis states its measured purity and identity by HPLC with mass confirmation. The catalogue item is stored at −20 °C, desiccated, conditions that slow oxidation and moisture-driven degradation.
Specification
| Field | Value |
|---|---|
| Catalogue name | Humanin |
| Length | 24 amino acids |
| Class | Mitochondrial-derived peptide |
| Category | Research peptides |
| Format | Lyophilised powder, glass vial, crimp seal, flip-top cap |
| House code | CS-HUMN-10 (10 mg) |
| Storage | −20 °C, desiccated |
| Lot documentation | RP-HPLC identity and measured purity, mass confirmation, per lot |
| Evidence stage | Mainly preclinical; human studies are observational |
Related reading: the NAD+ research review. The catalogue also lists MOTS-c.
Frequently asked questions
Why is humanin called a mitochondrial-derived peptide?
Because an open reading frame identical to its coding sequence was reported in the mitochondrial genome in 2003. The term groups it with other short peptides encoded there, such as MOTS-c.
How does humanin act?
That is unsettled. Cell studies report binding to Bax inside the cell and signalling through a CNTFR-alpha, WSX-1 and gp130 receptor complex at the surface; other partners have been proposed.
Has humanin been tested in people?
Registered human studies found measure humanin levels as a biomarker. None found administers the peptide.
What does a humanin certificate need to show?
An HPLC trace with measured purity and a mass result matching the native 24-residue sequence, ideally ruling out oxidised methionine and disulfide-linked dimers.
See it in the catalogue: Humanin.
For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.